Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53

Molecular Pharmacology

Volumn 53, Issue 5, 1998, Pages 819-826

  Jones, Neil A ^a   Turner, Jonathon ^a   McIlwrath, Amanda J ^b   Brown, Robert ^b   Dive, Caroline ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN RECOGNITION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; CISPLATIN; FEMALE; HUMANS; MEMBRANE PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031747118     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Anthoney DA, McIlwrath AJ, Gallagher AW, Edlin AR, and Brown R (1996) Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumour cells. Cancer Res 56:1374-1381.
2. Bayle JH, Elenbaas B, and Levine AJ (1995) The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through a nonspecific nucleic acid-binding activity. Proc Natl Acad Sci USA 92:5729-5733.
3. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Wang-Peng J, Lonie KG, Knutsen T, McKoy WM, Young RC, and Ozols RF (1987) Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414-418.
4. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, and Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55:678-684.
5. Chapman RS, Chresta CM, Herberg AA, Beere HM, Heer S, Whetton AD, Hickman JA, and Dive C (1995) Further characterisation of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. Cytometry 20:245-256.
6. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, and Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and -independent pathways. Nature (Lond) 362:849-852.
7. Dibner MD, Ireland KA, Koerner LA, and Dexter DL (1985) Polar solvent-induced changes in membrane lipid lateral diffusion in human colon cancer cells. Cancer Res 45:4998-5003.
8. Dive C and Hickman JA (1991) Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 64:192-196.
9. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, and Castle V (1995) Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 55:2576-2582.
10. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajweski S, Reed JC, and Young LS (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogen 11:1217-1228.
11. Gannon JV, Greaves R, Iggo R, and Lane DP (1990) Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for a mutant form. EMBO J 9:1595-1602.
12. L in the control of apoptosis in murine myeloma cells. Cancer Res 56:1451-1456.
13. Gregory RE and DeLisa AF (1993) Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin Pharm 12:401-415.
14. L. Cancer Res 56:1621-1628.
15. Hanada MC, Aime-Sempe C, Sato T, and Reed JC (1995) Structure-function analysis of Bcl-2 protein: identification of conserved domains important for homodimerisation with Bcl-2 and heterodimerisation with Bax. J Biol Chem 270:11962-11969.
16. Harris CC (1996) Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442-1455.
17. Hupp TR, Meek DW, Midgley CA, and Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71:875-886.
18. Hupp TR and Lane DP (1994) Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp Quant Biol 59:195-206.
19. Hupp TR and Lane DP (1995) Two distinct signalling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J Biol Chem 270:18165-18174.
20. Hupp TR, Sparks A, and Lane DP (1995) Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245.
21. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, and Hamilton TC (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47:689-897.
22. Liebermann DA, Hoffman B, and Steinman RA (1995) Molecular controls of growth arrest and apoptosis: p53-dependent and -independent pathways. Oncogene 11: 199-210.
23. Lowe SW, Schmitt EM, Smith SW, Osborne BA, and Jacks T (1993) P53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond) 362:847-849.
24. L protein content in HT29 cells. Oncogene 13:2631-2637.
25. Milner J (1995) Flexibility: the key to p53 function? Trends Biochem Sci 20:49-51.
26. Miyashita TS, Krajewski S, Krajewska M, Wang HG, Lin HK, Lieberman DA, Hoffman B, and Reed JC (1994a) Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805.
27. Miyashita TS, Harigai M, Hanada M, and Reed JC (1994b) Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res 54:3131-3135.
28. Miyashita TS and Reed JC (1995) Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.
29. Oltvai ZN, Milliman CL, and Korsmeyer SJ (1993) Bcl-2 heterodimerises in vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 74:609-619.
30. Oltvai ZN and Korsmeyer SJ (1994) Checkpoints of duelling dimers foil death wishes. Cell 79:189-192.
31. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita TS, Reed JC, and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced Bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562.
32. Reed JC, Miyashita T, Takayama S, Wang H, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, and Hanada M (1996) Bcl-2 family protein: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60:23-32.
33. L Cancer Res 55:2262-2265.
34. Selvakumaran M, Lin HK, Miyashita TS, Wang HG, Krajewski S, Reed JC, Hoffman B, and Liebermann DA (1994) Immediate early up-regulation of bax expression by p53 but not TGFα1: a paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798.
35. Shaw P, Freeman J, Bovey R, and Iggo R (1996) Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxyl-terminus. Oncogene 12:921-930.
36. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, and Newcomb EW (1996) Drug-induced apoptosis in B cell chronic lymphocytic leukaemia: relationship between p53 gene mutation and Bcl/Bax proteins in drug resistance. Oncogene 12:1055-1062.
37. Vasey P, Jones NA, Jenkins S, Dive C, and Brown R (1996) Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50:1536-1540.
38. Vaux DL, Cory S, and Adams LM (1988) Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature (Lond) 225:440-442.
39. 2/M arrest and apoptosis. Nat Med 2:72-79.
40. Yang E and Korsmeyer SJ (1996) Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood 88:386-401.